Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyGiancarlo Comi, O. R. Hommes, Massimo Filippi et al.|The Lancet|2001Cited by 1.1k
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Rogier Hintzen, Michelle Mellion et al.|The Lancet Neurology|2019Cited by 185
Genome-Wide Pharmacogenomic Analysis of the Response to Interferon Beta Therapy in Multiple SclerosisEsther Byun, Jorge R. Oksenberg, Stacy J. Caillier et al.|Archives of Neurology|2008Cited by 172
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1aFrederik Barkhof, Maria A. Rocca, Gordon Francis et al.|Annals of Neurology|2003Cited by 135
Metabolomic signatures associated with disease severity in multiple sclerosisPablo Villoslada, Azucena Castro, Cristina Alonso et al.|Neurology Neuroimmunology & Neuroinflammation|2017Cited by 111